改进的哈里斯·霍克斯基于优化的模糊k-最近邻近算法用于诊断阿尔茨海默病
Qian Zhang1, Jinhua Sheng2, Qiao Zhang3
1College of Computer Science and Technology, Hangzhou Dianzi University, Hangzhou, Zhejiang, 310018, China; Key Laboratory of Intelligent Image Analysis for Sensory and Cognitive Health, Ministry of Industry and Information Technology of China, Hangzhou, Zhejiang, 310018, China; School of Data Science and Artificial Intelligence, Wenzhou University of Technology, Wenzhou, Zhejiang, 325035, China.
Computers in biology and medicine
|September 5, 2023
概括
准确的阿尔茨海默病 (AD) 诊断对于早期治疗至关重要. 这项研究引入了一种使用优化的Fuzzy k-nearest neighbor (FKNN) 的增强框架,并采用了新的哈里斯·霍克斯优化 (HHO) 算法,以从MRI扫描中改进AD和轻度认知障碍 (MCI) 的分类.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 早期诊断阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 对于及时干预和减缓疾病进展至关重要.
- 磁共振成像 (MRI) 是可视化与AD和MCI相关的大脑变化的关键模式.
- 现有的诊断框架需要优化,以提高准确性和效率.
研究的目的:
- 开发和验证一个新的框架,准确地分类阿尔茨海默病 (AD) 和轻度认知障碍 (MCI).
- 引入一个改进的优化算法,SSFSHHO,以提高AD诊断中Fuzzy k-近邻 (FKNN) 模型的性能.
- 利用MRI数据进行强大的AD和MCI分类,使用拟议的SSFSHHO-FKNN框架.
主要方法:
- 磁共振成像 (MRI) 数据的预处理.
- 从预处理的MRI扫描中提取特征.
- 使用新的哈里斯·霍克斯优化 (HHO) 变体SSFSHHO优化 Fuzzy k-nearest neighbor (FKNN) 算法,集成Sobol序列和随机分数搜索 (SFS).
主要成果:
- 与经典的元启发算法和其他HHO变体相比,SSFSHHO算法在基准测试问题上表现优越.
- 在SSFSHHO-FKNN框架中,使用阿尔茨海默病神经成像倡议 (ADNI) 数据集的MRI扫描来实现AD和MCI的高分类准确性.
- 拟议的方法在AD分类任务中超过了现有的高性能优化和经典机器学习算法.
结论:
- 开发的SSFSHLO-FKNN框架为阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的早期和准确分类提供了一个有希望和有效的方法.
- 集成SSFSHHO显著提高了FKNN的参数优化,从而提高了诊断性能.
- 该框架识别相关特征的能力进一步巩固了其作为临床AD诊断中宝贵工具的潜力.
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


